<p>儘管腫瘤學是製藥行業中按收入計算最大的治療領域，但抗肥胖藥物在過去幾年中吸引了最多的關注。這個細分市場仍處於起步階段，預計在未來幾年將快速增長。許多大型和小型製藥公司都在尋求在這一領域產生重大影響。最成功的公司將獲得可觀的財務收益，並可能在此過程中實現超出市場的回報。</p>
<p>兩家相對不為人知的生物科技公司正在該領域開發有前景的療法，分別是 <strong>Terns Pharmaceuticals</strong>(TERN -7.64%) 和 <strong>Rhythm Pharmaceuticals</strong>(RYTM -2.57%)。如果這些生物科技公司能夠取得實質性進展，它們的股價可能會飆升。以下是投資者需要了解的內容。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzM4MjMvcGF0aWVudC1zZWxmLWFkbWluaXN0ZXJpbmctYS1zaG90LmpwZyZ3PTcwMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzM4MjMvcGF0aWVudC1zZWxmLWFkbWluaXN0ZXJpbmctYS1zaG90LmpwZyZ3PTcwMA"/></p>
<p>圖片來源：Getty Images。</p>
<h2>1. Terns Pharmaceuticals</h2>
<p>Terns Pharmaceuticals 是一家小型臨牀階段生物科技公司。該公司的主要候選藥物之一是 TERN-601，一種中期口服 GLP-1 候選藥物。Terns Pharmaceuticals 最近啓動了一項為期 12 周的二期臨牀試驗，旨在研究該藥物在減肥方面的效果。預計將在第四季度獲得數據。儘管幾種已批准的抗肥胖藥物正在產生可觀的銷售額，但口服藥物可以解決一些尚未解決的問題。與皮下注射相比，口服藥物的生產成本更低。</p>
<p>通過口服藥物，製藥公司將有機會擴大生產，針對更多患者，尤其是考慮到許多人對針頭幾乎過敏。TERN-601 仍處於中期研究階段。根據最近競爭生物科技和製藥公司在口服 GLP-1 藥物方面的發展，Terns Pharmaceuticals 要想給市場留下深刻印象並不容易。然而，如果它能為 TERN-601 提供強勁的結果，Terns Pharmaceuticals 的股價可能會在今年晚些時候飆升。</p>
<p>Terns Pharmaceuticals 還有其他管線候選藥物。它正在開發 TERN-501，作為潛在的代謝功能障礙相關性脂肪肝炎藥物，以及作為可能增強 GLP-1 藥物療效的聯合療法。Terns Pharmaceuticals 的 TERN-701 是一種潛在的癌症療法，目前處於一期研究階段，預計將在第四季度發佈數據。</p>
<p>也就是説，Terns 的表現將主要取決於 TERN-601 的進展。如果這款實驗性藥物在中期研究中失敗，股價將會暴跌。因此，儘管這裏有很大的上行潛力，但風險也高於平均水平。投資時需謹慎。</p>
<h2>2. Rhythm Pharmaceuticals</h2>
<p>Rhythm Pharmaceuticals 正瞄準減肥藥市場的一個細分領域。該公司正在開發幫助因各種罕見病症而導致肥胖的患者的藥物。Rhythm 的 Imcivree 於 2020 年首次獲得批准，適用於某些蛋白質缺乏患者的體重管理。該藥物的銷售額並不高，但正在取得進展。在第二季度，Rhythm Pharmaceuticals 的收入增長了 66.8%，達到了 4850 萬美元。</p>
<p>最近的臨牀進展使 Rhythm 的前景更加吸引人。它報告了 setmelanotide（Imcivree 的活性成分）在因下丘腦損傷導致肥胖患者中的三期強勁結果。Rhythm Pharmaceuticals 最近已提交了該藥物在這一適應症下的監管申請。預計到年底可能會獲得這一標籤擴展。</p>
<p>此外，該公司的 bivamelagon 在下丘腦肥胖症的二期研究中也取得了成功。Rhythm Pharmaceuticals 計劃明年啓動 bivamelagon 的三期研究。bivamelagon 的一個額外優勢是它是一種口服藥物，而 setmelanotide 則通過皮下注射給藥。bivamelagon 的強勁三期結果也可能推動股價上漲。Rhythm 的可尋址市場相對較小。</p>
<p>在 Imcivree 當前的適應症和下丘腦肥胖症潛在的新批准及標籤擴展之間，該公司在其關注的地區（美國、歐洲和日本）目標患者羣體可能高達 35,500 人。然而，針對這些特定病症的藥物仍然存在需求——大多數體重管理藥物並不針對這些病症。例如，目前沒有針對下丘腦肥胖症的體重管理藥物獲得批准。</p>
<p>Rhythm Pharmaceuticals 可能成為這些較小體重管理市場的主導者。在此之前，我們還需考慮幾項其他的二期和三期臨牀試驗，這些試驗可能會導致 setmelanotide 的更多標籤擴展。Rhythm Pharmaceuticals 仍然存在一定風險。setmelanotide 或 bivamelagon 的臨牀或監管挫折可能會對股價產生負面影響。但如果公司能夠推出 bivamelagon 併為 setmelanotide 增加新的適應症，未來五年內可能會帶來出色的回報。</p>

TERN

RYTM

<p>兩隻低調的生物技術股票，Terns Pharmaceuticals 和 Rhythm Pharmaceuticals，因其在抗肥胖市場的潛力而受到關注。Terns 正在開發 TERN-601，一種口服 GLP-1 候選藥物，預計將在第四季度公佈結果，而 Rhythm 則專注於針對罕見病症的體重管理藥物，收入增長達 66.8%。兩家公司面臨風險，但如果臨牀試驗成功並獲得監管批准，股票可能會大幅增長</p>

<p>While oncology is the largest therapeutic area in the pharmaceutical industry by revenue, the anti-obesity space has grabbed the most attention over the past couple of years. This niche is still in its infancy, though, and it is projected to grow rapidly at least through the end of the decade. Many drugmakers, both large and small, are seeking to make a significant impact in this area. The most successful ones will reap substantial financial benefits and perhaps generate market-crushing returns in the process.</p>
<div class="lb-trans"><p>儘管腫瘤學是製藥行業中按收入計算最大的治療領域，但抗肥胖藥物在過去幾年中吸引了最多的關注。這個細分市場仍處於起步階段，預計在未來幾年將快速增長。許多大型和小型製藥公司都在尋求在這一領域產生重大影響。最成功的公司將獲得可觀的財務收益，並可能在此過程中實現超出市場的回報。</p>
</div><p>Two relatively unknown biotechs that are developing promising therapies in this field are <strong>Terns Pharmaceuticals</strong>(TERN -7.64%) and <strong>Rhythm Pharmaceuticals</strong>(RYTM -2.57%). These biotechs could soar provided they deliver solid progress. Here's what investors need to know.</p>
<div class="lb-trans"><p>兩家相對不為人知的生物科技公司正在該領域開發有前景的療法，分別是 <strong>Terns Pharmaceuticals</strong>(TERN -7.64%) 和 <strong>Rhythm Pharmaceuticals</strong>(RYTM -2.57%)。如果這些生物科技公司能夠取得實質性進展，它們的股價可能會飆升。以下是投資者需要了解的內容。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzM4MjMvcGF0aWVudC1zZWxmLWFkbWluaXN0ZXJpbmctYS1zaG90LmpwZyZ3PTcwMA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F833823%2Fpatient-self-administering-a-shot.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>圖片來源：Getty Images。</p>
</div><h2>1. Terns Pharmaceuticals</h2>
<div class="lb-trans"><h2>1. Terns Pharmaceuticals</h2>
</div><p>Terns Pharmaceuticals is a small-cap, clinical-stage biotech. One of the company's leading candidates is TERN-601, a mid-stage oral GLP-1 candidate. Terns Pharmaceuticals has recently initiated a 12-week phase 2 clinical trial for this medicine in weight loss. It expects data from it in the fourth quarter. Although several approved anti-obesity medicines are generating substantial sales, an oral option could address some remaining issues. Oral pills come with lower manufacturing costs than subcutaneous injections.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals 是一家小型臨牀階段生物科技公司。該公司的主要候選藥物之一是 TERN-601，一種中期口服 GLP-1 候選藥物。Terns Pharmaceuticals 最近啓動了一項為期 12 周的二期臨牀試驗，旨在研究該藥物在減肥方面的效果。預計將在第四季度獲得數據。儘管幾種已批准的抗肥胖藥物正在產生可觀的銷售額，但口服藥物可以解決一些尚未解決的問題。與皮下注射相比，口服藥物的生產成本更低。</p>
</div><p>With oral medications, drugmakers will have the opportunity to ramp up manufacturing and target even more patients, especially considering many are practically allergic to needles. TERN-601 is still just in mid-stage studies. And based on recent developments from competing biotech and pharmaceutical companies working on oral GLP-1 medicines, it won't be easy for Terns Pharmaceuticals to impress the market. However, if it can post strong results for TERN-601, Terns Pharmaceuticals' shares could soar later this year.</p>
<div class="lb-trans"><p>通過口服藥物，製藥公司將有機會擴大生產，針對更多患者，尤其是考慮到許多人對針頭幾乎過敏。TERN-601 仍處於中期研究階段。根據最近競爭生物科技和製藥公司在口服 GLP-1 藥物方面的發展，Terns Pharmaceuticals 要想給市場留下深刻印象並不容易。然而，如果它能為 TERN-601 提供強勁的結果，Terns Pharmaceuticals 的股價可能會在今年晚些時候飆升。</p>
</div><p>Terns Pharmaceuticals does have other pipeline candidates. It is developing TERN-501 as a potential medicine for metabolic dysfunction-associated steatohepatitis and as a potential combination therapy that could enhance the efficacy of GLP-1 medicines. Terns Pharmaceuticals' TERN-701 is a potential cancer therapy in a phase 1 study, with an upcoming data readout scheduled for the fourth quarter.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals 還有其他管線候選藥物。它正在開發 TERN-501，作為潛在的代謝功能障礙相關性脂肪肝炎藥物，以及作為可能增強 GLP-1 藥物療效的聯合療法。Terns Pharmaceuticals 的 TERN-701 是一種潛在的癌症療法，目前處於一期研究階段，預計將在第四季度發佈數據。</p>
</div><p>That said, Terns' performance will largely depend on progress related to TERN-601. And if this investigational medicine fails in mid-stage studies, the stock will plummet. So, although there is plenty of upside potential here, there is also above-average risk. Invest accordingly.</p>
<div class="lb-trans"><p>也就是説，Terns 的表現將主要取決於 TERN-601 的進展。如果這款實驗性藥物在中期研究中失敗，股價將會暴跌。因此，儘管這裏有很大的上行潛力，但風險也高於平均水平。投資時需謹慎。</p>
</div><h2>2. Rhythm Pharmaceuticals</h2>
<div class="lb-trans"><h2>2. Rhythm Pharmaceuticals</h2>
</div><p>Rhythm Pharmaceuticals is targeting a niche of the market for weight management drugs. The company is developing medicines that help patients with obesity due to various rare conditions. Rhythm's Imcivree, first approved in 2020, is indicated for weight management in patients with certain protein deficiencies. The medicine doesn't generate much sales, but it is making progress. In the second quarter, Rhythm Pharmaceuticals' revenue increased by 66.8% to $48.5 million.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals 正瞄準減肥藥市場的一個細分領域。該公司正在開發幫助因各種罕見病症而導致肥胖的患者的藥物。Rhythm 的 Imcivree 於 2020 年首次獲得批准，適用於某些蛋白質缺乏患者的體重管理。該藥物的銷售額並不高，但正在取得進展。在第二季度，Rhythm Pharmaceuticals 的收入增長了 66.8%，達到了 4850 萬美元。</p>
</div><p>Recent clinical progress has made Rhythm's prospects more attractive. It reported strong phase 3 results for setmelanotide (the active ingredient in Imcivree) in patients with obesity resulting from hypothalamic damage. Rhythm Pharmaceuticals recently submitted regulatory applications for the medicine in this indication. It could earn this label expansion by the end of the year.</p>
<div class="lb-trans"><p>最近的臨牀進展使 Rhythm 的前景更加吸引人。它報告了 setmelanotide（Imcivree 的活性成分）在因下丘腦損傷導致肥胖患者中的三期強勁結果。Rhythm Pharmaceuticals 最近已提交了該藥物在這一適應症下的監管申請。預計到年底可能會獲得這一標籤擴展。</p>
</div><p>Elsewhere, the company's bivamelagon also aced a phase 2 study in hypothalamic obesity. Rhythm Pharmaceuticals plans to initiate phase 3 studies for bivamelagon next year. Bivamelagon has the added advantage of being an oral medicine, whereas setmelanotide is administered via subcutaneous injection. Strong phase 3 results for bivamelagon could also jolt the stock. Rhythm's addressable market is relatively small.</p>
<div class="lb-trans"><p>此外，該公司的 bivamelagon 在下丘腦肥胖症的二期研究中也取得了成功。Rhythm Pharmaceuticals 計劃明年啓動 bivamelagon 的三期研究。bivamelagon 的一個額外優勢是它是一種口服藥物，而 setmelanotide 則通過皮下注射給藥。bivamelagon 的強勁三期結果也可能推動股價上漲。Rhythm 的可尋址市場相對較小。</p>
</div><p>Between Imcivree's current indications and the potential new approvals and label expansions in hypothalamic obesity, the company is targeting a potential patient population of up to 35,500 patients in the regions it is focusing on: the U.S., Europe, and Japan. However, there is also a need for medications that target these conditions specifically -- most weight management medicines don't do that. There are no therapies approved for weight management in hypothalamic obesity, for example.</p>
<div class="lb-trans"><p>在 Imcivree 當前的適應症和下丘腦肥胖症潛在的新批准及標籤擴展之間，該公司在其關注的地區（美國、歐洲和日本）目標患者羣體可能高達 35,500 人。然而，針對這些特定病症的藥物仍然存在需求——大多數體重管理藥物並不針對這些病症。例如，目前沒有針對下丘腦肥胖症的體重管理藥物獲得批准。</p>
</div><p>Rhythm Pharmaceuticals could be the dominant player in these smaller weight management markets. That's before we add several other phase 2 and phase 3 clinical trials that could lead to even more label expansions for setmelanotide. Rhythm Pharmaceuticals remains somewhat risky. Clinical or regulatory setbacks with setmelanotide or bivamelagon could negatively impact the stock. But the company could deliver outstanding returns in the next five years, provided it can launch bivamelagon and add new indications to setmelanotide.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals 可能成為這些較小體重管理市場的主導者。在此之前，我們還需考慮幾項其他的二期和三期臨牀試驗，這些試驗可能會導致 setmelanotide 的更多標籤擴展。Rhythm Pharmaceuticals 仍然存在一定風險。setmelanotide 或 bivamelagon 的臨牀或監管挫折可能會對股價產生負面影響。但如果公司能夠推出 bivamelagon 併為 setmelanotide 增加新的適應症，未來五年內可能會帶來出色的回報。</p>
</div>

兩隻可能大幅上漲的冷門股票